[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Onan B, Onan IS, Polat B: Surgical resection of solitary metastasis of malignant melanoma to the right atrium. Tex Heart Inst J; 2010;37(5):598-601
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of solitary metastasis of malignant melanoma to the right atrium.
  • Malignant melanoma has a very high tendency to metastasize to the heart.
  • Although most cardiac metastases of melanomas are clinically silent, the lesions may present with life-threatening cardiac morbidities, including dysrhythmia, right ventricular outflow tract obstruction, myocardial dysfunction, pericardial effusion, or heart failure.
  • In selected patients who have a solitary intracardiac melanoma, surgical resection can provide relief from clinical symptoms and minimize potential cardiac sequelae of the tumor.
  • Because tumor embolization of cardiac melanoma has been reported, the presence of atrial metastatic melanoma can be another indication for surgery.Herein, we present the case of a 31-year-old man who had a right atrial metastatic melanoma of unknown primary origin.
  • He underwent surgical resection of the tumor before beginning a course of chemotherapy.

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Nov;75(3):203-7 [11088053.001]
  • [Cites] J Vasc Surg. 2002 Jul;36(1):191-3 [12096280.001]
  • [Cites] Semin Nucl Med. 2004 Oct;34(4):242-53 [15493002.001]
  • [Cites] Am J Cardiol. 1968 Apr;21(4):555-71 [5650736.001]
  • [Cites] J Vasc Surg. 1986 Mar;3(3):550-3 [3951038.001]
  • [Cites] Heart Lung. 2006 Sep-Oct;35(5):351-4 [16963367.001]
  • [Cites] Ann Thorac Surg. 1996 Apr;61(4):1255-7 [8607700.001]
  • [Cites] Mayo Clin Proc. 1996 Dec;71(12):1167-70 [8945488.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):844-6 [9527233.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Mar;15(3):373-5 [10333039.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • (PMID = 20978580.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953215
  • [Keywords] NOTNLM ; Endocardium/pathology / heart atria/surgery/ultrasonography / heart neoplasms/complications/diagnosis/pathology/secondary/surgery / image interpretation, computer-assisted/methods / melanoma/diagnosis/secondary/surgery / neoplasm metastasis / neoplasms, unknown primary / prognosis / treatment outcome
  •  go-up   go-down


2. Kitamura M, Wada N, Nagata S, Iizuka N, Jin YF, Tomoeda M, Yuki M, Naka N, Araki N, Yutani C, Tomita Y: Malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart: a case report. Diagn Pathol; 2010;5:2
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart: a case report.
  • A rare case is presented of a 61-year-old man with a malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart.
  • The primary tumor originated in the right thigh in 1982.
  • Since then, the patient has had repeated local recurrences in spite of repeated surgical treatment and adjuvant chemotherapy.
  • He has developed previous metastases of the lung and heart.
  • The patient died of cardiac involvement.
  • [MeSH-major] Heart Neoplasms / secondary. Nerve Sheath Neoplasms / secondary. Neurofibromatosis 1 / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Amputation. Autopsy. Biopsy. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Thigh. Treatment Outcome


3. Candeias CM, Luís I, Ribeiro J, Costa L, de Almeida LS, Gomes MM, Barreto L, Brito-Avô L, Ducla-Soares JL: Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin.
  • Angiosarcoma is the most common primary malignant tumour of the heart.
  • It is a rare and aggressive neoplasm that almost always has a short and fatal evolution.
  • By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise.
  • Body computed tomography scan disclosed a solid mass in the left atrium.
  • The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response.
  • The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients' lifespan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22347886.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027499
  •  go-up   go-down


Advertisement
4. Matsakas EP, Lazaros GA, Panou FK, Karavidas AI, Papalimberi EP, Scotis ID, Zacharoulis AA: Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade. Clin Cardiol; 2002 Feb;25(2):83-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade.
  • A partial pericardiectomy was performed to relieve the patient's symptoms, and histologic examination of a biopsy specimen showed features of a malignant, spindle cell, mesenchymal neoplasm.
  • The patient underwent surgical treatment during which the tumor was found to infiltrate the anterior surface of the right ventricle.
  • Histologically, the tumor was identified as a high-grade fibrosarcoma, and additional chemotherapy was given.
  • [MeSH-major] Cardiac Tamponade / etiology. Fibrosarcoma / diagnosis. Heart Neoplasms / diagnosis. Pericardium
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841156.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N: Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol; 2008 Sep;39(9):1385-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival.
  • Although cardiac sarcomas are rare in comparison to their soft tissue counterparts, they are the second most common type of primary cardiac neoplasm.
  • A series of 27 cardiac sarcomas removed at surgery for curative and diagnostic intent were reviewed for clinicopathologic features with correlation to available postoperative follow-up data in 17 patients.
  • There were 6 angiosarcomas, 6 myxofibrosarcomas, 3 malignant peripheral nerve sheath tumors, 3 leiomyosarcomas, 2 synovial sarcomas, 1 epithelioid hemangioendothelioma, 1 chondrosarcoma, 1 osteosarcoma, and 4 poorly differentiated sarcomas.
  • Six high-grade and 1 low-grade tumors were also treated with adjuvant chemotherapy and/or radiation.
  • Tumor grade appeared to be prognostically important in cardiac sarcoma.
  • [MeSH-major] Heart Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1949-51 [10892961.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):352-6 [12063709.001]
  • [Cites] J Heart Lung Transplant. 2002 Oct;21(10):1135-9 [12398881.001]
  • [Cites] Rev Esp Cardiol. 2003 Apr;56(4):408-11 [12689577.001]
  • [Cites] Chest. 2003 May;123(5):1766-8 [12740300.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Apr;52(2):77-81 [15103579.001]
  • [Cites] Ann Surg. 1980 Feb;191(2):127-38 [7362282.001]
  • [Cites] Hum Pathol. 1982 Jul;13(7):640-5 [7084941.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):943-5 [3840005.001]
  • [Cites] Chest. 1987 Jul;92(1):177-9 [3595230.001]
  • [Cites] Chest. 1987 Nov;92(5):860-2 [3665601.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:183-91 [2237900.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:192-5 [2237901.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):906-10 [2039319.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):999-1001 [2039335.001]
  • [Cites] Ann Thorac Surg. 1991 Oct;52(4):886-95 [1929651.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):387-95 [1728367.001]
  • [Cites] Am Heart J. 1992 Jan;123(1):232-4 [1729836.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):881-3 [1818549.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(3):233-6 [1287840.001]
  • [Cites] J Cardiovasc Surg (Torino). 1993 Dec;34(6):529-33 [8300722.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):374-82 [7997732.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Histopathology. 1997 Apr;30(4):349-52 [9147083.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):167-72 [9845736.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1624-8 [9862574.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Histopathology. 1999 Apr;34(4):295-304 [10231396.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):925-32 [16675225.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):188-9 [17409853.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):19-22 [17444167.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1134-42 [17914083.001]
  • (PMID = 18602663.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL063954
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS522251; NLM/ PMC4081532
  •  go-up   go-down


6. Akhter SA, McGinty J, Konys JJ, Giesting RM, Merrill WH, Wagoner LE: Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation. J Heart Lung Transplant; 2004 Dec;23(12):1447-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation.
  • Malignant fibrous histiocytoma (MFH) is an extremely rare primary cardiac tumor.
  • We describe a young patient who underwent orthotopic heart transplantation for an unresectable right ventricular MFH and presented 7 years later with a local recurrence in the native right atrium.
  • This was treated by complete resection of the right atrial tumor and adjuvant chemotherapy.
  • This case represents the only reported long-term survival following cardiac transplantation for MFH and describes our management strategy for local recurrence in this patient.
  • [MeSH-major] Heart Neoplasms / surgery. Heart Transplantation. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607678.001).
  • [ISSN] 1053-2498
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Fresneau B, Oberlin O, Brugières L, Valteau-Couanet D, Patte C: [Malignant primary cardiac tumors in childhood and adolescence]. Arch Pediatr; 2010 May;17(5):495-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary cardiac tumors in childhood and adolescence].
  • Primary heart tumors are uncommon in children.
  • The majority of them are benign, with only 10% malignant.
  • Among malignant cardiac tumors, sarcoma (rhabdomyosarcoma, angiosarcoma, synovial sarcoma) and lymphoma (Burkitt's lymphoma, large B-cell lymphoma, lymphoblastic lymphoma) predominate.
  • There are few published pediatric series on malignant primary cardiac tumors.
  • We report here 3 observations of primary malignant cardiac tumors, 2 cases of sarcoma (angiosarcoma and synovial sarcoma) and 1 case of Burkitt's lymphoma.
  • A precise pathological diagnosis is necessary for the proper management of these patients.
  • For sarcoma, treatment associates surgery and chemotherapy.
  • Surgery should be as complete as possible because of the lack of chemotherapy sensitivity of some sarcomas, mainly angiosarcoma and synovial sarcoma.
  • Therefore, the prognosis of cardiac sarcoma remains poor.
  • For primary cardiac lymphoma, management should not be different from lymphoma in other locations.
  • Chemotherapy is the main treatment, and surgery has to be used only when complications occur.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Diagnosis, Differential. Dyspnea / etiology. Echocardiography. Fatal Outcome. Female. Heart Atria / pathology. Heart Atria / surgery. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Pulmonary Heart Disease / diagnosis. Pulmonary Heart Disease / etiology. Superior Vena Cava Syndrome / diagnosis. Superior Vena Cava Syndrome / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20338733.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Van Veer H, Meuris B, Verbeken E, Herijgers P: Primary atrial fibrosarcoma of the heart. Cardiovasc Pathol; 2008 Sep-Oct;17(5):325-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary atrial fibrosarcoma of the heart.
  • The primary fibrosarcoma of the heart is a rare tumor.
  • There are no exact numbers about its incidence, but even among malignant cardiac tumors, only around 3% are fibrosarcomata.
  • Symptoms are nonspecific with signs of right or left heart failure depending on localization.
  • Diagnosis is thereby often delayed.
  • Primary treatment of choice is surgery, followed by several possible postsurgical adjuvant strategies.
  • [MeSH-major] Fibrosarcoma / pathology. Heart Atria / pathology. Heart Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cardiovascular Surgical Procedures. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Immunohistochemistry. Middle Aged. Mitral Valve / pathology. Mitral Valve / surgery. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402789.001).
  • [ISSN] 1054-8807
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Li B, Lei W, Shao K, Zhang C, Chen Z, Shi S, He J: Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res; 2007 Aug;17(4):239-42
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and prognosis of primary malignant melanoma of the esophagus.
  • Primary malignant melanoma of the esophagus is an extremely rare but highly aggressive tumor.
  • The preoperative diagnosis is complicated for the lack of specificity.
  • Unfortunately, the prognosis of primary malignant melanoma of the esophagus remains dismal from most literatures.
  • To better understand this special condition, we reviewed the medical records of patients with primary malignant melanoma of the esophagus in our center, retrospectively.
  • Only one patient, however, was pathologically diagnosed as primary malignant melanoma of the esophagus preoperatively.
  • Four of the six patients had metastasis to the liver, adrenal gland, heart and lymph nodes, respectively.
  • Our data show that primary malignant melanoma of the esophagus is a highly aggressive disease with poor prognosis.
  • Surgery remains the first selected therapy.
  • The role of radiotherapy and chemotherapy in the treatment of primary malignant melanoma of the esophagus is still uncertain.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Esophagectomy. Female. Humans. Immunohistochemistry / methods. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625454.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Reardon MJ, Walkes JC, Benjamin R: Therapy insight: malignant primary cardiac tumors. Nat Clin Pract Cardiovasc Med; 2006 Oct;3(10):548-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy insight: malignant primary cardiac tumors.
  • Benign cardiac tumors are resected with a high degree of success with modern cardiac surgical techniques.
  • Malignant cardiac tumors, however, continue to pose a therapeutic challenge to cardiac surgeons and oncologists because of the technical difficulty involved in extensive cardiac resections and the aggressive biological nature of the tumors.
  • The majority of malignant cardiac tumors are sarcomas and can be categorized as right heart sarcoma, left heart sarcoma or pulmonary artery sarcoma.
  • Right heart sarcomas are generally angiosarcomas, which infiltrate widely and metastasize early.
  • A combination of chemotherapy and surgical resection is the preferred therapy.
  • Left heart sarcomas, although large, are often less infiltrative and metastasize later than right heart sarcomas, but a similar approach to treatment is usually employed.
  • Surgical resection is more-frequently necessary for left heart sarcomas because of intracardiac blood flow obstruction and congestive heart failure, although the anatomic position and relation of these tumors to cardiac structures can complicate surgery.
  • We have developed and employed the technique of cardiac autotransplantation, which involves cardiac excision, ex vivo tumor resection with cardiac reconstruction, and cardiac reimplantation, to lessen these technical difficulties.
  • Pulmonary artery sarcomas can be treated by radiotherapy, as well as by the other therapies, because the myocardium can be avoided by the radiation fields.
  • Surgical resection of this sarcoma type often requires pneumonectomy and can require pulmonary root replacement.
  • [MeSH-major] Heart Neoplasms / surgery. Hemangiosarcoma / surgery. Histiocytoma, Malignant Fibrous / surgery. Pulmonary Artery / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cardiac Surgical Procedures. Chemotherapy, Adjuvant. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990840.001).
  • [ISSN] 1743-4297
  • [Journal-full-title] Nature clinical practice. Cardiovascular medicine
  • [ISO-abbreviation] Nat Clin Pract Cardiovasc Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


11. Reinecke P, Steckstor M, Schmitz M, Gabbert HE, Gerharz CD: Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart. Oncol Rep; 2004 Mar;11(3):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart.
  • Primary malignant fibrous histiocytoma (MFH) of the heart is a rare and highly malignant soft tissue tumor, which is largely resistant to conventional chemotherapy and radiotherapy.
  • Therefore, we analyzed growth inhibitory effects of different chemotherapeutic agents and mechanisms of drug resistance in the recently established cell line MFH-H derived from a human primary cardiac MFH.
  • The expression and function of multidrug resistance-related proteins, i.e. the P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance-related protein (LRP) were determined by FACScan and functional assays of cellular drug efflux.
  • [MeSH-major] Alkaloids / therapeutic use. Drug Resistance, Multiple. Heart Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Plant Extracts / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Separation. Cell Survival. Cells, Cultured. Coloring Agents / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Etoposide / pharmacology. Flow Cytometry. Humans. Inhibitory Concentration 50. P-Glycoprotein / metabolism. Paclitaxel / pharmacology. Phenotype. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Vault Ribonucleoprotein Particles / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767515.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Coloring Agents; 0 / P-Glycoprotein; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 298-93-1 / thiazolyl blue; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Sarjeant JM, Butany J, Cusimano RJ: Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs; 2003;3(6):407-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the heart: epidemiology and management of primary tumors and metastases.
  • Cardiac tumors, benign or malignant, are rare and most are benign.
  • The most common benign tumor is the cardiac myxoma.
  • Malignant cardiac tumors are usually sarcomas.
  • The pericardium can be the site of benign and malignant cardiac tumors, though metastatic tumors occur here far more commonly than do primary tumors.
  • Successful treatment for benign cardiac tumors is usually achieved by surgical resection.
  • Surgery for primary malignant tumors is, however, much less successful as complete resection is usually not possible.
  • Primary cardiac lymphoma may be successfully treated by chemotherapy.
  • Tumors that metastasize to the heart from other organs occur 100- to 1000-fold more commonly than primary cardiac tumors.
  • Metastatic spread to the heart has been identified in approximately one-fifth of all patients who have metastatic cancer with lung carcinoma being the most common primary tumor.
  • Symptoms of cardiac metastases vary, and they depend on the site and extent of the lesions.
  • Treatment varies depending on the pathology of the primary tumor.
  • However, the aim of treatment is usually symptomatic relief.
  • With the advent of AIDS, Kaposi's sarcoma and high grade B cell lymphomas have also been identified in cardiac tissue.
  • The aim of this article is to review the epidemiology, clinical presentation, pathology and treatment of cardiac tumors.
  • [MeSH-major] Heart Neoplasms
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Neoplasm Metastasis. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728061.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 62
  •  go-up   go-down


13. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Antemortem diagnosis is difficult and distant metastases are extremely rare.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Prognosis. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


14. Kutsal A, Tansal S, Okutan H, Tuncer I: Primary malignant mesenchymoma of the heart. Eur J Cardiothorac Surg; 2002 Jan;21(1):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesenchymoma of the heart.
  • Primary malignant cardiac tumours are uncommon, and cardiac malignant mesenchymoma is extremely rare.
  • A case of primary malignant mesenchymoma in a 41-year-old woman arousing from the left atrial septum, obstructing the mitral orifice by passing through it into the left ventricle is described.
  • The tumour was fully resected, and adjuvant chemotherapy was applied, but the patient had died by tumour recurrence in 8 months.
  • [MeSH-major] Heart Neoplasms / surgery. Mesenchymoma / surgery
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11788281.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Hoffmeier A, Scheld HH, Tjan TD, Schneider M, Kerber S, Schmidt C, Schmid C: Ex situ resection of primary cardiac tumors. Thorac Cardiovasc Surg; 2003 Apr;51(2):99-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex situ resection of primary cardiac tumors.
  • The prognosis of malignant heart tumors is pessimistic; 50% of patients die within 6 months.
  • No optimal therapy has been established, and standardized therapeutic concepts have not been developed due to the low incidence of this disease.
  • In most cases, chemotherapy and radiotherapy have not shown any survival benefit compared to surgical treatment.
  • Here, we report on two patients in whom radical resection of heart tumors could be accomplished only after explantation of the heart.
  • [MeSH-major] Heart Neoplasms / surgery. Hemangiosarcoma / surgery. Myxoma / surgery. Transplantation, Autologous
  • [MeSH-minor] Adult. Echocardiography. Heart Atria / surgery. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thorac Cardiovasc Surg. 2003 Oct;51(5):293-4 [14571349.001]
  • (PMID = 12730820.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Women and pericardial neoplastic manifestations of the heart and pericardium].
  • In the Western world more than 450,000 women succumb to heart disease annually.
  • Despite the proportions, most women believe that heart disease is a man's disease and that they will die of breast cancer.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • Malignant heart tumors are less common.
  • Most often they are different types of sarcomas, which have a poor outcome and affect more males than females.
  • Metastatic tumors of the heart are 100 times more common than the primary ones.
  • To prevent death from tamponade, pericardiocentesis, in addition to the systemic chemotherapy, is mandatory, best when instillation of chemotherapeutics (cisplatin or thiotepa) or radioisotopes is given into the pericardial sac to prevent recurrence of the effusion.
  • However, more of the malignant tumors may be curable if exactly diagnosed at an earlier stage.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • CONCLUSION: Females are more often affected by primary cardiac tumors than males with an excellent outcome.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / secondary. Heart Neoplasms / epidemiology. Heart Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Registries. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Elliott KS, Borowsky ME, Bakdounes K, Huang J, Abulafia O, Lee YC: Malignant thymoma metastatic to the pelvis: a rare case and considerations for management. Gynecol Oncol; 2005 Oct;99(1):228-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant thymoma metastatic to the pelvis: a rare case and considerations for management.
  • We present an unusual case of recurrent thymoma metastatic to the pelvis and review treatment experience employing surgical, radiotherapeutic and medical modalities.
  • CASE REPORT: The present case is that of a 46-year-old woman with recurrent thymoma metastatic to a distal pelvic lymph node.
  • Resection of the pelvic recurrence followed many years of local and systemic treatment for her thoracic primary tumor.
  • Her case is unique for its involvement of pelvic anatomy and her clinical course marked by treatment-related congestive heart failure.
  • CONCLUSION: While the indolent clinical course of thyomoma frequently necessitates re-treatment and multi-modality therapy in patients suffering recurrences, treatment selection must take into account potential long-term morbidity and attendant quality of life.
  • When anatomically and technically feasible, resection of recurrent disease should be considered in attempts to avoid potential cumulative and long-term toxicity resultant from radiotherapy and chemotherapy.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pelvic Neoplasms / secondary. Thymoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055177.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol; 2007 Feb 10;25(5):493-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD).
  • We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs).
  • PATIENTS AND METHODS: Treatment for low- and high-risk HD with doxorubicin, bleomycin, vincristine, and etoposide (ABVE) or dose-intensified ABVE with prednisone and cyclophosphamide (ABVE-PC), respectively, was followed by low-dose radiation.
  • The number of chemotherapy cycles was determined by rapidity of the initial response.
  • Patients were assigned randomly to receive DRZ (n = 239) or no DRZ (n = 239) concomitantly with chemotherapy to evaluate its potential to decrease adverse cardiopulmonary outcomes.
  • RESULTS: Ten patients developed SMN.
  • Six of eight patients developed AML/MDS, and both solid tumors (osteosarcoma and papillary thyroid carcinoma) occurred in recipients of DRZ.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chelating Agents / adverse effects. Hodgkin Disease / drug therapy. Leukemia, Myeloid / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced. Razoxane / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Cohort Studies. Enzyme Inhibitors / adverse effects. Female. Follow-Up Studies. Heart Diseases / chemically induced. Heart Diseases / prevention & control. Humans. Incidence. Lung Diseases / chemically induced. Lung Diseases / prevention & control. Male. Neoplasm Staging. Osteosarcoma / chemically induced. Risk Assessment. Risk Factors. Thyroid Neoplasms / chemically induced. Time Factors. Topoisomerase II Inhibitors


19. Lumia D, Laganà D, Verna E, Mangini M, Canì A, Carrafiello G, Fugazzola C: Recurrence of intracardiac large B-cell non-Hodgkin's lymphoma (NHL) encasing and nearly obliterating the right coronary artery: a case report. Minerva Chir; 2010 Jun;65(3):383-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among malignant tumors of the heart, primary malignant lymphomas are unusual and they are typically non-Hodgkin's B-cell cancers.
  • A 73-year-old man affected by non-Hodgkin lymphoma (NHL) treated with four cycle of chemotherapy and radiotherapy was admitted to the Emergency Department for chest pain.
  • The ECG-gated angio-multidetector computed tomography (MDCT) examination confirmed a solid mass in the right ventricle encasing the proximal-middle tract of the right coronary artery (RCA); RCA stenosis was confirmed by coronary angiography.
  • After trans-thoracic CT-guided biopsy the mass was characterized as a recurrence of NHL and the patient started a new cycle of chemotherapy.
  • [MeSH-major] Coronary Stenosis / etiology. Heart Neoplasms / complications. Lymphoma, Large B-Cell, Diffuse / complications. Neoplasm Recurrence, Local / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20668424.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Bien E, Stachowicz-Stencel T, Balcerska A, Godzinski J, Kazanowska B, Perek-Polnik M, Madziara W, Rybczynska A, Kurylak A, Zalewska-Szewczyk B, Peregud-Pogorzelski J: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study. Eur J Cancer Care (Engl); 2009 Jul;18(4):411-20
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children.
  • Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006.
  • Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each).
  • Complete primary excision was unfeasible even in local stages.
  • All patients received supplementing chemotherapy with no response in four.
  • Relapsed patients received chemotherapy +/- radiotherapy and surgery (three).
  • Complete primary excision is unfeasible, even in seemingly local stages.
  • The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Male. Poland / epidemiology. Prognosis. Radiotherapy. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490008.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Coutts MA, Borthwick NJ, Hungerford JL, Cree IA: Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma. Pathol Oncol Res; 2006;12(3):184-7
MedlinePlus Health Information. consumer health - Vaginal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uveal melanoma differs from cutaneous melanoma in many ways, including its pattern of metastasis, and exhibits latency with clinical evidence of metastasis sometimes appearing many years after primary diagnosis.
  • Further investigation revealed widespread metastatic disease and the patient was not fit for chemotherapy.
  • The immediate cause of death was cardiac tamponade due to a malignant effusion secondary to cardiac metastasis.
  • [MeSH-minor] Aged, 80 and over. Endometrial Neoplasms / secondary. Female. Heart Neoplasms / secondary. Humans. Liver Neoplasms / secondary. Neoplasm Metastasis. Postmenopause

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol (Copenh). 1970;48(6):1113-28 [5537253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9 [14578381.001]
  • [Cites] Am J Ophthalmol. 1985 Nov 15;100(5):666-8 [4061546.001]
  • [Cites] Retina. 1981;1(2):100-6 [7348822.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Am J Ophthalmol. 1978 Oct;86(4):557-64 [707604.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Dec;130(6):1727-8 [16308029.001]
  • [Cites] Acta Ophthalmol (Copenh). 1963;43:SUPPL 75:1-220 [14050563.001]
  • [Cites] J Med Ethics. 2005 Jun;31(6):360-1 [15923487.001]
  • [Cites] J Med Ethics. 2004 Dec;30(6):561-4 [15574445.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):549-56 [7413144.001]
  • [Cites] Acta Ophthalmol (Copenh). 1982 Apr;60(2):161-82 [7136531.001]
  • [Cites] Int Ophthalmol. 1985 Mar;7(3-4):175-81 [3997359.001]
  • [Cites] Br J Ophthalmol. 1999 May;83(5):588-94 [10216060.001]
  • [Cites] Arch Ophthalmol. 1999 Nov;117(11):1558-9 [10565531.001]
  • [Cites] Cancer Invest. 1997;15(2):98-105 [9095204.001]
  • [Cites] Acta Cytol. 1978 Nov-Dec;22(6):503-6 [282750.001]
  • [Cites] Chest. 2001 Dec;120(6):2115 [11742953.001]
  • [Cites] APMIS. 1989 Nov;97(11):1018-24 [2590533.001]
  • [Cites] Cancer. 1974 Mar;33(3):729-31 [4815575.001]
  • (PMID = 16998600.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Belmadani K, Amahzoune B, Selkane C, Boulahya A, el Fakir Y, al Bouzidi A, el Kirat A: [Invasive thymoma extending into the superior vena cava and the right atrium: a case report and review of the literature]. Ann Cardiol Angeiol (Paris); 2001 Jun;50(4):217-23
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transthoracic echocardiography supplemented by the echocardiography transoesophageal pose the cardiac diagnosis of tumor, and it is the thoracic tomodensitometry which highlights a tumoral process mediastinal of malignant pace invading the left inominal venous trunk, the higher vena cava and extending in the right auricle.
  • The diagnosis of certainty is carried by the endobronchial biopsy and the puncture tomodensitometric biopsy under control of the mediastinal mass after anatomopathological examination.
  • Under chemotherapy, the evolution over 18 months is marked by the absence of cardiovascular complications in spite of the non regression of the tumoral mass.
  • The surgery when it is possible, remains the principal therapeutic measurement which really proved reliable.
  • [MeSH-major] Heart Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Thymoma / diagnosis. Thymus Neoplasms / diagnosis. Vascular Neoplasms / diagnosis. Vena Cava, Superior
  • [MeSH-minor] Aged. Heart Atria. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555596.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Stefanou D, Goussia AC, Arkoumani E, Metafratzi ZM, Syminelakis S, Arkoumani E, Agnantis NJ: Mucoepidermoid carcinoma of the thymus: a case presentation and a literature review. Pathol Res Pract; 2004;200(7-8):567-73
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucoepidermoid carcinoma of the thymus is an unusual, but well-recognized variant of thymic malignant tumors.
  • As heart function tests were normal, the patient underwent radiologic examination, which showed a well-demarcated mass in the anterior mediastinum.
  • Histologic examination of the surgically resected mass showed features of a mucoepidermoid carcinoma with associated infiltration of the pleural tissue.
  • Postoperative radiotherapy and chemotherapy were performed, and the patient died two months after initial diagnosis.
  • In case of the absence of metastatic disease or other common primary neoplasms of the thymus, the diagnosis of a mucoepidermoid thymic carcinoma should be taken into consideration, although this tumor is rare.
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pleura / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462505.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 11
  •  go-up   go-down


24. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD: Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst; 2010 Aug 4;102(15):1114-30
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life.
  • This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems.
  • Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies.
  • Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1140-9 [15990020.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):200-7 [15999104.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66 [16030303.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):521-4 [15968690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9 [17689884.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):799-807 [18618574.001]
  • [Cites] J Cancer Surviv. 2008 Sep;2(3):159-68 [18654861.001]
  • [Cites] Nat Rev Neurosci. 2008 Oct;9(10):768-78 [18802446.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6284-8 [18829510.001]
  • [Cites] BMC Clin Pharmacol. 2008;8:7 [18796166.001]
  • [Cites] Health Phys. 2008 Nov;95(5):677-86 [18849702.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(R2):R102-8 [18852197.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3247-55 [18852128.001]
  • [Cites] J Med Internet Res. 2008;10(4):e34 [18974036.001]
  • [Cites] Arch Ital Urol Androl. 2008 Sep;80(3):99-102 [19009865.001]
  • [Cites] N Engl J Med. 2008 Nov 20;359(21):2195-207 [18997196.001]
  • [Cites] Am J Epidemiol. 2008 Dec 1;168(11):1233-46 [18922999.001]
  • [Cites] Cancer J. 2008 Nov-Dec;14(6):414-9 [19060607.001]
  • [Cites] Nat Genet. 2009 Jan;41(1):25-34 [19079261.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):334-43 [19075285.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):860-3 [10597212.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):866-9 [10597214.001]
  • [Cites] Neurotoxicology. 1999 Dec;20(6):883-7 [10693969.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1075-6 [10744098.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1725-32 [10764433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55 [16751059.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Sep;132(9):557-60 [16741728.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6480-6 [17085662.001]
  • [Cites] Heart. 2006 Dec;92(12):1752-9 [16621883.001]
  • [Cites] CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53 [17135691.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):623-31 [17096341.001]
  • [Cites] Circulation. 2006 Dec 12;114(24):2710-38 [17130340.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):8-16 [17130180.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):241-8 [17060482.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):708-14 [17228018.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):209 [17359909.001]
  • [Cites] J Urol. 2007 Apr;177(4):1330-4; discussion 1334 [17382725.001]
  • [Cites] Arch Phys Med Rehabil. 2007 Apr;88(4):529-36 [17398257.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4341-3 [17906197.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] J Biol. 2006;5(7):22 [17125495.001]
  • [Cites] J Clin Oncol. 2007 Nov 10;25(32):5121-7 [17991931.001]
  • [Cites] Pharmacogenomics J. 2008 Feb;8(1):23-8 [17457342.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):217-24 [18176561.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2389-95 [15800331.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1685-95 [15843671.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3061-8 [15860864.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):18-21 [15878096.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71 [10904090.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):245-55, vi [18395148.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1817-23 [18398146.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1845-53 [18306372.001]
  • [Cites] Nat Genet. 2008 May;40(5):638-45 [18372903.001]
  • [Cites] Am J Epidemiol. 2008 May 15;167(10):1226-34 [18385206.001]
  • [Cites] Acta Oncol. 2008;47(1):63-70 [17934892.001]
  • [Cites] Radiat Res. 2008 Jul;170(1):49-59 [18582155.001]
  • [Cites] JAMA. 2008 Jul 9;300(2):197-208 [18612117.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1551-7 [18628407.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2009 Feb;5(2):113-21 [19165223.001]
  • [Cites] Hum Genet. 2009 Mar;125(2):173-80 [19089452.001]
  • [Cites] JAMA. 2009 Feb 18;301(7):753-62 [19224752.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Mar;15(2):296-301 [19203434.001]
  • [Cites] PLoS Genet. 2009 Mar;5(3):e1000433 [19300499.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1360; author reply 1361 [19321875.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1360; author reply 1361 [19330894.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2129-36 [19289622.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2114-6 [19307494.001]
  • [Cites] Blood. 2009 May 28;113(22):5575-82 [19299336.001]
  • [Cites] Nature. 2009 May 28;459(7246):587-91 [19349959.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2779-86 [19414680.001]
  • [Cites] JAMA. 2009 Jun 24;301(24):2553-62 [19549972.001]
  • [Cites] Nat Genet. 2009 Jul;41(7):816-9 [19483685.001]
  • [Cites] J Natl Cancer Inst. 2009 Jul 1;101(13):946-58 [19535780.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jul;2(7):617-24 [19584075.001]
  • [Cites] Am J Epidemiol. 2009 Jul 15;170(2):135-47 [19465742.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1394-5 [16204683.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37 [16204692.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):779-85 [15963629.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Nov;56(5):535-42 [15947931.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 2;97(21):1580-8 [16264178.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9130-7 [16301596.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):256-62 [16364249.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] Methods Enzymol. 2005;401:116-35 [16399382.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):467-75 [16421423.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):776-83 [16338099.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):251-9 [16170559.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):918-24 [16484702.001]
  • [Cites] Circulation. 2006 May 16;113(19):2335-62 [16702488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 [17537913.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Science. 2007 Jun 8;316(5830):1488-91 [17478681.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2352-9 [17557948.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2705-15 [17595271.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2709-18 [17602076.001]
  • [Cites] N Engl J Med. 2007 Aug 2;357(5):443-53 [17634449.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):427-37 [17701890.001]
  • [Cites] Am J Med Sci. 2007 Aug;334(2):115-24 [17700201.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1248-56 [17686826.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3800-1 [17646665.001]
  • [Cites] Am J Hypertens. 2007 Sep;20(9):942-8 [17765133.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1438-47 [17350159.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1448-54 [17544206.001]
  • [Cites] Urol Oncol. 2005 May-Jun;23(3):193-200 [15907721.001]
  • [Cites] Support Care Cancer. 2005 Jul;13(7):540-8 [15660224.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1321-34 [10064598.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):941-7 [10071288.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):533-44 [17405998.001]
  • [Cites] Urology. 2007 Apr;69(4):748-53 [17445663.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Transl Med. 2007;5:70 [18162130.001]
  • [Cites] Mutat Res. 2008 Mar 1;639(1-2):20-6 [18082847.001]
  • [Cites] Pharmacogenet Genomics. 2008 Mar;18(3):253-62 [18300947.001]
  • [Cites] N Engl J Med. 2008 Mar 20;358(12):1240-9 [18354102.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):623-9 [17974553.001]
  • [Cites] J Sex Med. 2008 Apr;5(4):998-1012 [18221290.001]
  • [Cites] J Psychosom Res. 2008 Apr;64(4):363-71 [18374735.001]
  • [Cites] Int J Radiat Biol. 2003 Feb;79(2):137-43 [12569017.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1107-18 [12637478.001]
  • [Cites] Hum Reprod. 2003 Apr;18(4):796-801 [12660273.001]
  • [Cites] N Engl J Med. 2003 Apr 3;348(14):1356-64 [12672864.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):387-402 [12726864.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1216-21 [12763208.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1249-55 [12820379.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1195-214 [12832285.001]
  • [Cites] Science. 2003 Jul 18;301(5631):386-9 [12869766.001]
  • [Cites] Eur Urol. 2003 Sep;44(3):322-8 [12932930.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1633-7 [14583761.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 14;311(2):264-6 [14592408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1168-74 [14652276.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):749-55 [14974917.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):701-6 [15010071.001]
  • [Cites] Genome Res. 2004 May;14(5):812-9 [15123581.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):973-8 [14729580.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):615-20 [15196853.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4353-6 [15205351.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] Lancet. 2004 Sep 11-17;364(9438):937-52 [15364185.001]
  • [Cites] Ann Intern Med. 1979 Jun;90(6):929-31 [375794.001]
  • [Cites] Science. 1980 Apr 11;208(4440):198-200 [7361117.001]
  • [Cites] Ann Intern Med. 1981 Sep;95(3):288-92 [6168223.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1251-6 [4040958.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2765-70 [2413982.001]
  • [Cites] Prog Clin Biol Res. 1985;203:47-60 [2421339.001]
  • [Cites] Br J Cancer. 1986 Jul;54(1):19-23 [3524645.001]
  • [Cites] Toxicol Pathol. 1986;14(2):247-57 [3764321.001]
  • [Cites] Cancer Surv. 1987;6(3):477-510 [3440244.001]
  • [Cites] Circulation. 2008 Jul 22;118(4):355-62 [18559695.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):8-16 [18648940.001]
  • [Cites] Eur J Cancer. 1992;28A(8-9):1358-61 [1515251.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):60-2 [7677936.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):415-24 [8445415.001]
  • [Cites] Gynecol Oncol. 1993 Aug;50(2):147-58 [8375728.001]
  • [Cites] Eur J Cancer. 1993;29A(10):1373-6 [8398261.001]
  • [Cites] Cancer Treat Rev. 1999 Feb;25(1):47-58 [10212589.001]
  • [Cites] Curr Biol. 1999 Jul 1;9(13):699-702 [10395545.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):173-9 [10458231.001]
  • [Cites] Toxicol Pathol. 2004 Sep-Oct;32(5):577-90 [15603542.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Mar;55(3):231-6 [15619138.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2865-7 [15591336.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):196-202 [15629612.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):599-608 [15659507.001]
  • [Cites] Neurobiol Dis. 2005 Mar;18(2):305-13 [15686959.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1105-11 [15705913.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1200-8 [15718317.001]
  • [Cites] Hear Res. 2005 Mar;201(1-2):121-31 [15721567.001]
  • [Cites] Support Care Cancer. 2005 Aug;13(8):637-46 [15756585.001]
  • [Cites] Radiat Res. 2005 Sep;164(3):237-44 [16137195.001]
  • [Cites] Brain Behav Immun. 2009 Aug;23(6):868-74 [19362138.001]
  • [Cites] Pharmacogenomics J. 2009 Oct;9(5):347-53 [19434073.001]
  • [Cites] Acta Oncol. 2009;48(6):842-9 [19412812.001]
  • [Cites] Disabil Rehabil. 2009;31(21):1762-72 [19479510.001]
  • [Cites] Am J Epidemiol. 2009 Aug 1;170(3):269-79 [19498075.001]
  • [Cites] Neoplasma. 2009;56(6):473-9 [19728753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1420-9 [19931732.001]
  • [Cites] Nat Genet. 2009 Dec;41(12):1345-9 [19898482.001]
  • [Cites] J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95 [19940282.001]
  • [Cites] Pharmacol Rev. 2009 Dec;61(4):413-29 [20038569.001]
  • [Cites] Int J Androl. 2010 Jun 1;33(3):500-6 [19207614.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(2):163-7 [3280153.001]
  • [Cites] Cancer Lett. 1988 May;40(1):83-91 [2453267.001]
  • [Cites] Clin Sci (Lond). 1988 Aug;75(2):203-7 [3409636.001]
  • [Cites] J Clin Oncol. 1988 Nov;6(11):1728-31 [2460594.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1457-61 [2476531.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;25(1):1-9 [2686850.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):347-55 [2299374.001]
  • [Cites] Br J Cancer. 1990 Apr;61(4):639-43 [2109999.001]
  • [Cites] Am Heart J. 1991 Jan;121(1 Pt 2):293-8 [1985385.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):359-63 [1713639.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):149-53 [1727376.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):574-9 [1372350.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jun;15(6):399-405 [15900213.001]
  • [Cites] Thromb Res. 2000 Sep 1;99(5):503-9 [10973681.001]
  • [Cites] Acta Oncol. 2000;39(4):519-22 [11041115.001]
  • [Cites] Anticancer Drugs. 2000 Sep;11(8):639-43 [11081456.001]
  • [Cites] J Urol. 2001 Jan;165(1):93-6 [11125372.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1323-31 [11483345.001]
  • [Cites] Chest. 2001 Aug;120(2):617-24 [11502668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11592-7 [11553769.001]
  • [Cites] Br J Cancer. 2001 Oct 19;85(8):1219-25 [11710838.001]
  • [Cites] J Am Soc Nephrol. 2001 Dec;12(12):2683-90 [11729237.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):222-8 [11885998.001]
  • [Cites] Nurs Stand. 2000 Aug 30-Sep 5;14(50):41-6 [11975163.001]
  • [Cites] Acta Oncol. 2002;41(4):323-33 [12234023.001]
  • [Cites] J Clin Invest. 2002 Sep;110(6):835-42 [12235115.001]
  • [Cites] Pharmacogenetics. 2002 Oct;12(7):543-53 [12360105.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):91-6 [12488299.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • [Cites] Annu Rev Med. 2003;54:73-87 [12471176.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] Int Urol Nephrol. 1993;25(3):215-20 [8225820.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):677-83 [7928500.001]
  • [Cites] Miner Electrolyte Metab. 1994;20(4):201-13 [7845323.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):35-40 [7536027.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] J Urol. 1996 Feb;155(2):574-8 [8558663.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):239-45 [8996148.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):253-62 [9135497.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):95-102 [9212009.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):844-50 [9258096.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13245-54 [9582369.001]
  • [Cites] Circulation. 1998 May 12;97(18):1837-47 [9603539.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:325-32 [9679563.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):657-60 [9681081.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] Cancer J Sci Am. 1998 Nov-Dec;4(6):385-9 [9853138.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):602-6 [9973207.001]
  • (PMID = 20585105.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U56CA118635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  • [Number-of-references] 251
  • [Other-IDs] NLM/ PMC2914759
  •  go-up   go-down


25. Green GJ, Weitzman SS, Pencharz PB: Resting energy expenditure in children newly diagnosed with stage IV neuroblastoma. Pediatr Res; 2008 Mar;63(3):332-6
MedlinePlus Health Information. consumer health - Toddler Nutrition.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with stage IV neuroblastoma (NBIV) are often malnourished at time of diagnosis, observed as high as 50%.
  • Our hypothesis was that children diagnosed with NBIV have an increased REE, which normalizes with cancer treatment.
  • Changes in nutritional status from time of diagnosis in response to nutritional support were examined.
  • REE and nutritional evaluation were obtained three times: at diagnosis before starting treatment, where tumor burden is expected to be highest; after two courses of chemotherapy, where some response to treatment is expected; and after surgical excision of the primary tumor, where there was presumably minimal residual disease.
  • Fifty percent of our subjects were malnourished at diagnosis.
  • Because REE is not increased in NBIV, it is concluded that malnutrition seen in NBIV is not due to increased energy needs, but is likely due to decreased intake because of the intra-abdominal mass and malignant malaise.
  • [MeSH-minor] Anthropometry. Calorimetry, Indirect. Child. Child, Preschool. Female. Heart Rate. Humans. Male. Neoplasm Staging. Nutrition Assessment. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287973.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down






Advertisement